已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial

医学 扎那米韦 奥司他韦 临床终点 临床试验 神经氨酸酶抑制剂 人口 内科学 随机对照试验 儿科 外科 2019年冠状病毒病(COVID-19) 传染病(医学专业) 疾病 环境卫生
作者
Francisco M. Marty,Joan Vidal-Puigserver,Carol L. Clark,Sandeep K. Gupta,Esperanza Merino,Denis Garot,Marianne J. Chapman,Frédérique Jacobs,Eduardo Rodríguez-Noriega,Petr Husa,Denise Shortino,Helen Watson,Phillip J. Yates,Amanda Peppercorn
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:5 (2): 135-146 被引量:102
标识
DOI:10.1016/s2213-2600(16)30435-0
摘要

Neuraminidase inhibitors are effective for the treatment of acute uncomplicated influenza. However, there is an unmet need for intravenous treatment for patients admitted to hospital with severe influenza. We studied whether intravenous zanamivir was a suitable treatment in this setting.In this international, randomised, double-blind, double-dummy, phase 3 trial, we recruited patients aged 16 years or older with severe influenza admitted to 97 hospitals from 26 countries. We randomly assigned patients (1:1:1 stratified by symptom onset ≤4 days or 5-6 days) to receive 300 mg or 600 mg intravenous zanamivir, or standard-of-care (75 mg oral oseltamivir) twice a day for 5-10 days; patients were followed up for 28 days. The randomisation schedule, including stratification, was generated using GlaxoSmithKline's RandAll software. Patients, site study staff, and sponsor were masked to study treatment. The primary endpoint was time to clinical response-a composite of vital sign stabilisation and hospital discharge-in the influenza-positive population. The trial was powered to show an improvement of 1·5 days or greater with 600 mg intravenous zanamivir. Pharmacokinetic, safety, and virology endpoints were also assessed. This trial is registered with ClinicalTrials.gov, number NCT01231620.Between Jan 15, 2011, and Feb 12, 2015, 626 patients were randomly assigned to receive 300 mg intravenous zanamivir (n=201), 600 mg intravenous zanamivir (n=209), or 75 mg oral oseltamivir (n=205) twice a day; 11 patients discontinued the study before receiving any study treatment. 488 (78%) of 626 patients had laboratory-confirmed influenza. Compared with a median time to clinical response of 5·14 days in the 600 mg intravenous zanamivir group, the median time to clinical response was 5·87 days (difference of -0·73 days, 95% CI -1·79 to 0·75; p=0·25) in the 300 mg intravenous zanamivir group and 5·63 days (difference of -0·48 days, 95% CI -2·11 to 0·97; p=0·39) in the oseltamivir group. Four patients with influenza A/H1N1pdm09 in the oseltamivir group developed H275Y resistance mutations. Adverse events were reported in 373 (61%) of treated patients and were similar across treatment groups; the most common adverse events (300 mg intravenous zanamivir, 600 mg intravenous zanamivir, oseltamivir) were diarrhoea (10 [5%], 15 [7%], 14 [7%]), respiratory failure (11 [5%], 14 [7%], 11 [5%]), and constipation (7 [3%], 13 [6%], 10 [5%]). 41 (7%) treated patients died during the study (15 [7%], 15 [7%], 11 [5%]); the most common causes of death were respiratory failure and septic shock.Time to clinical response to intravenous zanamivir dosed at 600 mg was not superior to oseltamivir or 300 mg intravenous zanamivir. All treatments had a similar safety profile in hospitalised patients with severe influenza.GlaxoSmithKline.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
XIE完成签到,获得积分10
1秒前
牧青发布了新的文献求助10
1秒前
微风完成签到,获得积分10
2秒前
3秒前
逆流的鱼发布了新的文献求助10
3秒前
科目三的应助被五本笔记采纳,获得10
3秒前
zzh完成签到,获得积分10
3秒前
上官若男的应助被Audrey采纳,获得10
4秒前
杰尼龟完成签到,获得积分10
5秒前
yansie完成签到,获得积分10
5秒前
无心的千万完成签到,获得积分10
5秒前
感动沛容发布了新的文献求助10
6秒前
6秒前
FashionBoy的应助被liugm采纳,获得10
7秒前
12秒前
秋风的应助被Feng5945采纳,获得20
12秒前
15秒前
15秒前
16秒前
Ava的应助被高高采纳,获得10
18秒前
18秒前
18秒前
19秒前
阿南发布了新的文献求助10
19秒前
ccccelia发布了新的文献求助20
19秒前
拼搏的问薇完成签到,获得积分10
21秒前
邱邱科研发布了新的文献求助10
22秒前
22秒前
22秒前
牧青发布了新的文献求助10
22秒前
典雅胜发布了新的文献求助10
23秒前
24秒前
25秒前
被风吹过的路的应助被wulin314采纳,获得10
25秒前
桐桐的应助被666采纳,获得10
25秒前
CodeCraft的应助被皮特科研淘宝采纳,获得10
26秒前
小萝卜发布了新的文献求助10
27秒前
Orange的应助被Audrey采纳,获得10
28秒前
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189671
求助须知:如何正确求助?哪些是违规求助? 9576938
关于积分的说明 21850391
捐赠科研通 7787625
什么是DOI,文献DOI怎么找? 3435756
关于科研通互助平台的介绍 2559813
邀请新用户注册赠送积分活动 2482624